Good day, and welcome to the Calithera Biosciences' Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. As a reminder, this call may be recorded. I would now like to turn the call over to Stephanie Wong, CFO. You may begin..

Thank you, operator. Good afternoon, everyone, and welcome to our second quarter 2022 conference call. Joining me today are Susan Molineaux, Founder, President and CEO; and Emil Kuriakose, Chief Medical Officer.

Earlier this afternoon, we issued a press release, which included an overview of our second quarter 2022 financial and operational results, which can be accessed through our website at calithera.com.

Before we begin, I would like to remind you that today's discussion will include statements about our future expectations, plans and prospects that constitute forward-looking statements for purposes of the Safe Harbor provisions under the Private Securities Litigation Reform Act of 1995.

Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those discussed in the Risk Factors section of our periodic filings with the SEC.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so even if our views change.

Please note that this call is being recorded. And with that, I will turn the call over to Susan..

Thanks, Stephanie. Good afternoon everyone, and thank you for joining us for today's conference call.

When we spoke last quarter, I noted that Calithera was off to an exciting start in 2022 and I'm pleased to say that this momentum has continued in recent months, as we work to advance our pipeline of investigational small molecule oncology compounds to address the needs of biomarker-defined patient populations.

The most notable developments, of course were the initiations and enrollment of the first patients in our Phase II clinical trials of mivavotinib in relapsed/refractory non-GCB diffuse large B-cell lymphoma or DLBCL in June; and sapanisertib in relapsed/refractory NRF2-mutated squamous, non-small cell lung cancer in the first week of July.

We remain on track to report data from both of these monotherapy studies by the first quarter of 2023, and look forward to sharing additional details along the way. Further, updates on both programs were shared at the Pan Pacific Lymphoma Conference and the World Conference for Lung Cancer. At the Pan Pacific Conference last month, Dr.

Reem Karmali of Northwestern University presented a poster detailing the design of the Phase II mivavotinib study. And just last week at World Lung, Dr.

Jonathan Riess of UC Davis Comprehensive Cancer Center presented during a mini oral session, the findings from an investigator-initiated multicenter Phase I/II dose escalation study of sapanisertib in combination with telaglenastat in advanced non-small cell lung cancer patients.

Preclinical studies have shown that combining telaglenastat and sapanisertib demonstrated synergistic antitumor activity. As you recall, we are not developing telaglenastat at this time. However, we are interested in this combination and look forward to the results of this investigator-initiated study.

Emil will provide more details on these presentations in his remarks. We continue to believe that by focusing on well-characterized genetic vulnerabilities with molecules that have already shown single-agent activity, we will be able to generate Phase II data with targeted efficient study designs, such as those we are currently enrolling.

We believe that these studies have the potential to lead us to efficient path to approval in biomarker-defined patient populations. Turning to our preclinical programs. We have continued to advance our pipeline of synthetic lethality targets, most notably VPS4A and VPS4B.

And as you heard on last quarter's earnings call, we shared the first data from this program at AACR in April. We are continuing to advance multiple compound series, through lead optimization and look forward to updating you on our progress as they advance towards first-in-human clinical studies.

We expect to provide further updates on our preclinical efforts by year-end. And with that said, I will pass the call over to Emil, to provide additional details on our progress. .

To confirm, previously observed single-agent activity in non-GCB DLBCL; determine activity in patients with MyD88 or CD79B mutated DLBCL; and further refine dose and schedule. MyD88 or CD79B mutation status will be determined using ctDNA-based liquid next-gen sequencing after randomization.

The primary endpoints are safety and overall response rate as determined by independent radiology review and secondary endpoints include duration of response, PFS and complete response rate. Similar to sapanisertib, the results of this study could position us to initiate a registrational trial targeting accelerated approval in third line DLBCL.

As Susan also noted in July, we presented a trial and progress poster at the Pan Pacific Lymphoma Conference, detailing the rationale and design of this Phase 2 study, based on a combined analysis of two prior studies of mivavotinib monotherapy in relapsed or refractory DLBCL.

In these studies mivavotinib has the recommended Phase 2 dose of 100 milligrams Q daily showed a compelling overall response rate of 53% with a median duration of response of 15.7 months in non-GCB patients.

In addition to the monotherapy study, we plan to pursue combination strategies aimed at evaluating mivavotinib with novel and standard of care therapies in earlier lines of DLBCL and other lymphomas. We look forward to sharing additional details on these plans as we advance further. Turning to our preclinical development efforts.

As Susan stated, we have continued to advance our pipeline of synthetic lethality targets. As a reminder, the data shared at the AACR annual meeting demonstrated a synthetic lethal interaction between gene paralog VPS4A and VPS4B, validating these as attractive targets in tumors that have lost either paralogs.

These data were the first preclinical evidence supporting a newly discovered series of compounds designed to target these proteins for cancer treatment. We're currently advancing multiple theories to lead optimization and look forward to updating you on the program by the end of this year.

With that, I'll pass it over to Stephanie for an update on our financials..

Thank you, Emil. An overview of our financial results, were included in today's press release. I will briefly review our results on this call. Our cash and cash equivalents totaled $41.8 million at June 30, 2022, which we expect will be sufficient to meet our operating plans through the second quarter of 2023.

R&D expenses for the second quarter of 2022 were $7.8 million compared to $12.8 million in the same period last year. The decrease was primarily due to decreases in the telaglenastat and CB-280 programs, partially offset by increases in the sapanisertib and mivavotinib programs.

G&A expenses for the second quarter of 2022 were $3.6 million compared to $4.5 million in the same period last year. The decrease was primarily due to decreased personnel-related costs. Other income net for the second quarter of 2022 was $2.3 million, primarily attributable to the decrease in fair value of warrant liabilities.

Net loss for the three months ended June 30, 2022 was $9.1 million. And with that, I will now return the call back over to Susan..

Thank you, Stephanie. And with that, operator, we're happy to open the line for questions..

Our first question comes from Jonathan Chang with SVB Securities. Your line is open..

Hi, guys. Thanks for taking my questions.

First question, can you discuss the rationale for the doses being evaluated in the sapanisertib Phase 2 study? And how do those compare to what was used in the recently presented World Lung combination study as well as other prior studies?.

Sure, Jonathan. Great question. So, the rationale for the monotherapy dose schedule is primarily the extensive amount of data we had from the monotherapy trials that Takeda had conducted as well as extensive PK/PD modeling.

And in brief, that showed that the doses of three milligrams to four milligrams you avoided the dose-limiting toxicities of Gi Tox and your primary AE with hypoglycemia which is very manageable and did not lead to discontinuation. And so we already also saw that aside from the safety profile that that was an active dose in the study run by Paul Kay.

We're also evaluating two milligrams BID again based on the PK/PD and PK safety modeling, given that if Gi Tox are not Cmax related that you can get to a higher cumulative dose of four milligrams with the BID schedule given that the drug has a half-life around six to seven hours. So you could get more exposure with the same safety profile.

So that was the rationale for the monotherapy doses we're evaluating. In terms of their combination data that's presented, they presented data on their first dose level which is two milligrams QD combined with 800 milligrams BID of telaglenastat. So the starting doses are similar for sapanisertib.

However, given that it's a combination with two drugs each of which have their own unique safety profile it's not exactly easy to extrapolate from combination safety data to the monotherapy. So we would consider those separate..

Understood, makes sense.

So maybe zooming out from the specific dosing question, what would you say are the key takeaways from the investigator study presented at World Lung with the sapanisertib plus telaglenastat combination? And what are the implications for your ongoing efforts?.

Yeah. I think the main key takeaway given that it's still a small data set and dose escalation is that so far the combination looks very tolerable. And we're especially encouraged by the early clinical activity we're seeing.

We think it's at least even in the small numbers and a total proof of concept again that in NRF2-mutant squamous lung cancer patients had a partial response.

So it definitely encouraging on both fronts from safety and efficacy and from a wider angle, I think that data complements nicely with the monotherapy data as we generate that to provide potential development paths for both mono and combo..

Got it and just one last question for me, I know you guys just started the Phase 2 studies but can you provide any color on at least the initial progress of those Phase 2 studies for sapanisertib and mivavotinib? And just talk about your level of confidence that you guys will be able to provide meaningful updates by the first quarter of 2023?.

Right. So we're not providing detailed interim enrollment updates. I mean, I can tell you that we have started enrollment on both types are being activated and patients are actively being screened and enrolled.

So, again as we said previously, given that, we're really looking at populations where these two drugs have already shown single-agent activity. We have a short time to respond for both drugs. And we have a well-characterized safety profile. And these are the reasons we're still guiding to the data in first quarter of 2023..

Got it. Thanks for taking my questions..

Sure. Thanks..

Our next question comes from Roger Song with Jefferies. Your line is open..

Great. Thank you for taking my question.

Maybe just a follow-up on the Phase 2 data readouts, maybe can you just comment on the expectation for the data readouts given you started? And what will be the go-no-go decision criteria for the -- if you will have the first initial data readouts? And what will be considered as the winning scenario for the initial readout? Thank you..

Yeah.

I mean, again to reiterate the point on the fact that the data that we're expecting or our response data based on efficacy data that we already have a bar for based on previous data from both drugs in the specific biomarker-defined populations, we think that we are still on track in terms of getting to meaningful data by 1Q 2023 based on the timing by which we started the enrollment and the rate at which we're opening sites.

So aside from that we haven't provided detailed guidance on exact numbers/go/no-go decisions. Beyond that, we expect meaningful data by that time point..

Understood. Okay.

And then with the World Lung Conference the combo data I think that Susan mentioned, you're not planning to develop the telaglenastat -- telaglenastat stand-alone, but would you -- would you sponsor your own combo study, or it may depend on the Phase 2 sapanisertib data then you want the study to go with the combo?.

Yeah. Right. As Susan said and we said, we're not developing telaglenastat at this time with any sort of trial sponsored trials. But we're interested in the outcome of this ISP. Our primary focus right now is on these monotherapy development paths for both sapanisertib and mivavotinib. That's where our full focus and efforts are right now.

But I think it will be a nice complementary data set that reads out in parallel to both of the monotherapy efforts that could guide us depending on how they look..

Got it. Okay. Maybe last question for us is the financial the cash runway.

Given you will read out data in 1Q and your current cash runway is to 2Q next year, just curious any flexibility in your cash runway will be, or any other way to extend the current cash runway to go a little bit further beyond the data catalyst?.

Hi, Roger, it's Stephanie. Thanks for the question. We certainly are evaluating that cash runway continuously. And also we're mindful of making sure that we can execute these programs. So as we make decisions, we will update everyone of any changes to our plan..

Got it. Thank you. That's all I have. Thank you..

Thanks, Roger..

There are no further questions. I'd like to turn the call back over to Susan Molineaux for any closing remarks..

Thank you, and thanks for all joining us today. Have a good evening. Goodbye..

This concludes the program. You may now disconnect..